NES and acute myeloid leukemia: Similarly, while the data clearly involve NESTIN+ cells in antioxidant protection, in vivo BSO treatment might deplete GSH in various cell types contributing to the final outcome—a synergistic effect to reduce LSCs when combined with standard chemotherapy mimicking clinical AML induction therapy.